BD a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral...
Biocom California, the association representing the California life science industry, and KoreaBIO, a life science trade association which seeks to solid...
Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases Strengthens QIAGEN Digital Insigh...
Nelipak® Corporation (“Nelipak®”), a leading global provider of healthcare packaging solutions for medical device, diagnostic, pharma...
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin...
Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer pati...
ANPD001 was well tolerated with no major safety issues in low-dose cohort Patients showed early improvements in patient-reported and clinician-re...
- Patients treated with VCN-01 (zabilugene almadenorepvec) plus standard gemcitabine/nab-paclitaxel chemotherapy had increased overall survival, progress...
GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCe...
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfoli...
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentat...
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces today a new organizati...
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of d...
© 2025 Biopharma Boardroom. All Rights Reserved.
